DeFi Daily News
Tuesday, June 3, 2025
Advertisement
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos
No Result
View All Result
DeFi Daily News
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos
No Result
View All Result
DeFi Daily News
No Result
View All Result
Home Other News Health

rewrite this title Medicare Will Not Cover GLP-1 Drugs for Weight Loss

Alice Park by Alice Park
April 7, 2025
in Health
0 0
0
rewrite this title Medicare Will Not Cover GLP-1 Drugs for Weight Loss
0
SHARES
0
VIEWS
Share on FacebookShare on TwitterShare on Telegram
Listen to this article


rewrite this content using a minimum of 1000 words and keep HTML tags

The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a proposal initiated by the Biden Administration to cover weight-loss drugs like Wegovy and Zepbound for its beneficiaries.

Medicare and Medicaid recipients can be reimbursed for the medications to treat diabetes, but currently the anti-obesity versions of these drugs will not be covered. As an obesity treatment, Wegovy, made by Novo Nordisk, comes with a slightly higher dose for treating obesity than doses for diabetes; the medication is otherwise the same. For Zepbound, developed by Lilly, it’s the same drug and administered in the same dose as Mounjaro, which is used to treat diabetes.

The Biden proposal would have included coverage of Wegovy and Zepbound to treat obesity under Medicare Part D for Medicare Advantage.

“While today’s announcement was limited, we hope that with the confirmation of the new CMS director, the Trump Administration will move forward to finalize the definition of obesity. It is essential that CMS regulations are aligned with current medical science—and that means recognizing obesity as a serious chronic disease,” a spokesperson from Novo Nordisk said in a statement to TIME.

A Lilly spokesperson said in a statement to TIME that the company “is disappointed in the MA-Part D rule because it is not the best reading of the statute and impacts patient access to obesity treatments,” referring to the program that allows enrollees to receive coverage of prescription drugs, including through private plans and through Medicare Advantage. “We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind.”

How Weight Loss Drugs Work

The decision not to expand coverage to include obesity treatment would mean nearly 7.5 million Medicare and Medicaid recipients won’t be reimbursed for the drug to help them lose weight. Government health care financing analysts noted in Sept. 2024 that the high cost of the drugs would result in higher government spending with “little information on longer-term effects of the drugs.”

However, health experts have raised concerns that denying coverage could lead to additional health costs for insurers, as scientists are discovering that the drugs come with many other health benefits. The drugs have already received additional indications from the U.S. Food and Drug Administration to lower the risk of heart disease and obstructive sleep apnea. And researchers are currently studying them for other benefits as well, including reducing the risk of kidney, liver, and brain diseases like Alzheimer’s and addiction.

and include conclusion section and FAQs section at the end. do not include the title. Add a hyperlink to this website http://defi-daily.com and label it “DeFi Daily News” for more trending news articles like this



Source link

Tags: CoverdrugsGLP1LossMedicarerewritetitleWeight
ShareTweetShare
Previous Post

Trump Tariffs: Stocks Lose $10 Trillion in Value

Next Post

we just got the biggest news for bitcoin so far…. and most are ignoring it

Next Post
we just got the biggest news for bitcoin so far…. and most are ignoring it

we just got the biggest news for bitcoin so far.... and most are ignoring it

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
  • Trending
  • Comments
  • Latest
rewrite this title Haliey Welch Breaks Silence on Hawk Tuah Coin Collapse

rewrite this title Haliey Welch Breaks Silence on Hawk Tuah Coin Collapse

May 6, 2025
The Future of Blockchain: An Inside Look at Cardano

The Future of Blockchain: An Inside Look at Cardano

July 18, 2024
Boeing machinists refuse latest offer, prolonging bruising six-week strike

Boeing machinists refuse latest offer, prolonging bruising six-week strike

October 23, 2024
I Have Fallen Into The Personal Loan Trap

I Have Fallen Into The Personal Loan Trap

May 2, 2025
Moralis Web3: Enterprise-Grade Crypto PnL API for Tracking Wallet Profit & Loss

Moralis Web3: Enterprise-Grade Crypto PnL API for Tracking Wallet Profit & Loss

July 24, 2024
I Built The DREAM Office Setup!

I Built The DREAM Office Setup!

November 30, 2024
rewrite this title Analyst Suggests Altcoin Recovery May Follow Bitcoin’s Final Cycle Stage—Here’s Why

rewrite this title Analyst Suggests Altcoin Recovery May Follow Bitcoin’s Final Cycle Stage—Here’s Why

June 2, 2025
rewrite this title Michael Saylor’s Strategy Plans Stock IPO to Fund Bitcoin Buys, Operations – Decrypt

rewrite this title Michael Saylor’s Strategy Plans Stock IPO to Fund Bitcoin Buys, Operations – Decrypt

June 2, 2025
rewrite this title with good SEO Bitcoin Price At 0,000 And Ethereum At ,000? Analyst Says Altcoin Season Is Coming | Bitcoinist.com

rewrite this title with good SEO Bitcoin Price At $200,000 And Ethereum At $10,000? Analyst Says Altcoin Season Is Coming | Bitcoinist.com

June 2, 2025
rewrite this title Nike Is Selling Air Max Plus Sneakers for Nearly 40% Off Right Now, and Shoppers Say They're Super Comfortable

rewrite this title Nike Is Selling Air Max Plus Sneakers for Nearly 40% Off Right Now, and Shoppers Say They're Super Comfortable

June 2, 2025
rewrite this title Robinhood Seals Bitstamp Acquisition, Marks Entry into Crypto Trading

rewrite this title Robinhood Seals Bitstamp Acquisition, Marks Entry into Crypto Trading

June 2, 2025
rewrite this title Jesus Guerrero’s Cause of Death: How the Celebrity Hairstylist Died

rewrite this title Jesus Guerrero’s Cause of Death: How the Celebrity Hairstylist Died

June 2, 2025
DeFi Daily

Stay updated with DeFi Daily, your trusted source for the latest news, insights, and analysis in finance and cryptocurrency. Explore breaking news, expert analysis, market data, and educational resources to navigate the world of decentralized finance.

  • About Us
  • Blogs
  • DeFi-IRA | Learn More.
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Defi Daily.
Defi Daily is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos

Copyright © 2024 Defi Daily.
Defi Daily is not responsible for the content of external sites.